Provider of government program administration services, including health and human services eligibility and workforce programs.
Provider of government program administration services, including health and human services eligibility and workforce programs.
Is paid under multi-year government contracts, either per transaction handled, on a fixed fee or at cost plus a margin, so a lost rebid can remove a large block of work at once. Beyond the US it runs benefits and assessment programmes for governments in the UK, Australia and Canada.
Moat: narrow (regulatory licence, scale, switching costs). Deep expertise administering complex government programs and long-term contracts create high switching costs.
Headquarters: Reston, Virginia · Founded: 1975 · Employees: 37,200
Size MAXIMUS (MMS) is a United States Industrials company (Miscellaneous Commercial Services) with a market value of $3.42B, the 1448th largest of 3,085 United States companies the cockpit tracks. Shares closed at $65.26 on 18 Nov 2026.
Performance Over six months the shares gained 8.5%, against +16.2% for the median peer and -2.2% for the United States market (cap-weighted) — 8th lowest of 21 in its peer set.
Growth Revenue fell 3.3% over the last twelve months (peer median +13.6%); the operating margin is 10.8% (peer median 11.2%).
Valuation It trades at 7.9× forward earnings against a peer median of 15.0× (2nd cheapest of 19).
Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -18 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.5 points above its cost of capital (7.1% WACC).
Backlog Backlog (remaining performance obligations) was $230M at 30 Jun 2026, down 30% on a year earlier — 0.0 years of trailing revenue. Backlog detail →
Short interest Short interest is 5.9% of the free float (30 Oct 2026).
Next results Next results expected around 19 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $5.25B | $5.43B | $5.31B | $4.90B | $4.63B |
| Revenue growth | — | +2% | +8% | +6% | — |
| Gross profit | $1.26B | $1.24B | $1.16B | $934M | $849M |
| EBITDA | $705M | $702M | $627M | $457M | $453M |
| Net income | $371M | $319M | $307M | $162M | $204M |
| Free cash flow | $433M | $366M | $383M | $224M | $234M |
| Capital expenditure | $36.3M | $63.2M | $132M | $90.7M | $56.1M |
| Total debt | $1.73B | $1.44B | $1.28B | $1.43B | $1.51B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| MAXIMUS MMS | $3.42B | +9% | -3% | 11% | 7.9× | -8.2% |
| Conduent CNDT | n/a | -30% | n/a | n/a | n/a | n/a |
| Accenture ACN | $134B | +27% | +6% | 15% | 15.5× | 1.7% |
| ICF International ICFI | $1.40B | +14% | -5% | 8% | 10.4× | -2.5% |
| Serco SRP.L | $3.23B | -7% | +1% | 5% | 13.7× | 0.8% |
| Capita CPI.L | $406M | -32% | -16% | 5% | 21.5× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MMS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.8% | -2.5% | 4th highest of 21 |
| 6-month return | +8.5% | +16.2% | 8th lowest of 21 |
| Distance from 52-week high | -34.7% | -14.2% | 4th lowest of 21 |
| Revenue growth (TTM) | -3.3% | +13.6% | 2nd lowest of 21 |
| Operating margin | 10.8% | 11.2% | 10th lowest of 21 |
| Forward P/E | 7.9× | 15.0× | 2nd cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -8.2% | 0.8% | 3rd least demanding of 16 |
| Growth delivered (Del g) | +9.4% | +13.2% | 7th lowest of 16 |
| Hurdle (Req g minus delivered) | -17.6 pp | -9.4 pp | 7th least demanding of 16 |
| ROIC minus cost of capital | +6.5 pp | +2.8 pp | 5th highest of 17 |
| EV / EBITDA | 7.1× | 9.2× | 5th cheapest of 16 |
| Net debt / EBITDA | 2.2× | 0.7× | 5th most indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| MAXIMUS MMS | United States | $3.42B | +9% | -3% | 11% | 7.9× | -8.2% | +9.4% |
| Loomis LOOMIS.ST | Sweden | $3.47B | +15% | +1% | 11% | 13.5× | -8.7% | +9.7% |
| MITIE MTO.L | United Kingdom | $3.48B | +18% | +11% | 3% | 14.1× | 14.3% | +17.6% |
| Serco SRP.L | United Kingdom | $3.23B | -7% | +1% | 5% | 13.7× | 0.8% | +4.9% |
| ABM Industries ABM | United States | $3.21B | +38% | +6% | 5% | 13.0× | -1.1% | +7.9% |
| Shenzhen Fortune Trend Technology 688318.SS | China | $3.13B | -28% | -3% | 56% | 64.8× | n/a | n/a |
| East Buy 1797.HK | Hong Kong | $3.79B | +21% | +34% | 11% | 36.2× | 17.3% | +54.3% |
| TriNet TNET | United States | $2.95B | +51% | -4% | 6% | 14.5× | -3.7% | +4.4% |
| PhysicsWallah PWL.NS | India | $3.99B | +13% | +35% | 1% | 118.1× | n/a | n/a |
| Centre Testing International 300012.SZ | China | $4.00B | +3% | +15% | 16% | 22.2× | 14.4% | +13.2% |
| Dizal Pharmaceutical 688192.SS | China | $4.02B | +9% | +720% | 69% | 7.8× | -11.0% | +95.9% |
| Inventurus Knowledge Solutions IKS.NS | India | $2.88B | -2% | +43% | 28% | 28.1× | 25.8% | +45.8% |
| SAI Life Sciences SAILIFE.NS | India | $4.07B | +59% | +16% | 22% | 87.2× | n/a | n/a |
| Jianshe Industry Group (Yunnan) 002265.SZ | China | $2.78B | -20% | +42% | 5% | n/a | 23.6% | +47.9% |
| CoreCivic CXW | United States | $2.77B | +50% | +27% | 10% | 14.6× | n/a | n/a |
| GEO GEO | United States | $4.22B | +37% | +15% | 13% | 15.5× | 5.7% | +2.3% |
| Pluxee PLX.PA | France | $2.75B | +4% | +1% | 28% | 9.2× | n/a | n/a |
| S-1 012750.KS | South Korea | $2.73B | +36% | +1% | 7% | 23.8× | -6.4% | +5.4% |
| JHT Design 603061.SS | China | $2.68B | -31% | +93% | 34% | n/a | 41.1% | +30.4% |
| Alsok 2331.T | Japan | $4.36B | +23% | +7% | 9% | 13.5× | -4.5% | +4.9% |
| Huron Consulting HURN | United States | $2.68B | +58% | +12% | 12% | 16.7× | -3.4% | +14.3% |
MAXIMUS reported $230M of remaining performance obligations at 30 Jun 2026, down 30% from a year earlier and down 8% from the previous quarter. That is 0.0 years of trailing revenue already under contract. Book-to-bill last quarter: 0.98.